Cargando…
Murine Models of Myelofibrosis
Myelofibrosis (MF) is subtype of myeloproliferative neoplasm (MPN) characterized by a relatively poor prognosis in patients. Understanding the factors that drive MF pathogenesis is crucial to identifying novel therapeutic approaches with the potential to improve patient care. Driver mutations in thr...
Autores principales: | Jacquelin, Sebastien, Kramer, Frederike, Mullally, Ann, Lane, Steven W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563264/ https://www.ncbi.nlm.nih.gov/pubmed/32842500 http://dx.doi.org/10.3390/cancers12092381 |
Ejemplares similares
-
Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis
por: Kramer, Frederike, et al.
Publicado: (2020) -
Captopril mitigates splenomegaly and myelofibrosis in the Gata1
(low) murine model of myelofibrosis
por: Corey, Seth J., et al.
Publicado: (2018) -
Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013) -
Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models
por: Dutta, Avik, et al.
Publicado: (2022) -
The Role of Navitoclax in Myelofibrosis
por: Pandravada, Sasirekha, et al.
Publicado: (2021)